- Scientific outlet Stat explains that Pfizer's vaccine success is promising for three other efforts.
- Approval of other vaccines would hasten the distribution of immunization.
- The stock market rally may have considerable room to run.
A COVID-19 vaccine is at hand – the earth-shattering news from Pfizer and BioNTech has sent markets surging. Immunization efforts have been in the works for many months and the world was hopeful for a breakthrough before the end of the year. Nevertheless, the announcement is a massive development.
The pharma firms say that the vaccine is 90% effective in preventing infections and has no safety issues after conducting a 43,500-strong Phase 3 trial. Pfizer has not been waiting for the results to begin producing doses, with some countries are already pre-ordering them. However, production bottlenecks and freezing storage temperatures may have
Investors may ask themselves – is everything already priced in? Probably not.
Scientific publication STAT has provided details on the groundbreaking development which consists of a critical factor. They say that the efforts by AstraZeneca, Modena Johnson use a similar approach – a pre-fusion spike as their immunogen – which means a high probability of success for their efforts as well.
Here is a tweet by Helen Branswell, senior writer and expert on infectious diseases with Stat:
2. It is also a really promising sign for the multiple other #Covid19 vaccines coming up behind Pfizer, as this statement from @CEPIvaccines points out. They all target the same protein on the #SARSCoV2 virus. Looks like it is a solid approach. pic.twitter.com/AoSVK9KBHm
— Helen Branswell (@HelenBranswell) November 9, 2020
If all four covid vaccines receive emergency approvals, they could all begin distributing their solutions to the world rapidly. Shortening the time-to-market would allow economies a quicker return to the old, pre-pandemic, normal.
For investors, that means the market rally has more room to run with every such approval. Pfizer is the winner in the race, but the others may be winners as well – and so could humanity and stock bulls.
Update: Dr. Anthony Fauci, the NIH Director, has said that Moderna's vaccine may yield similar results to that of Pfizer.
More Pfizer jumps after covid vaccine news, but is vulnerable to competition
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended Content
Editors’ Picks
EUR/USD loses traction, retreats below 1.0600
EUR/USD lost its recovery momentum and declined below 1.0600 in the American session on Friday, erasing a portion of its daily gains in the process. Nevertheless, the risk-positive market atmosphere after PCE inflation data helps the pair limit its losses.
GBP/USD turns negative on the day below 1.2200
GBP/USD reversed its direction and slumped below 1.2200 in the American session on Friday after rising above 1.2270 earlier in the day. Position readjustments and profit-taking on the last trading day of the quarter seems to be weighing on Pound Sterling.
Gold reverses direction, drops below $1,860
Following a steady rebound toward $1,880 on Friday, Gold price made a sharp U-turn and turned negative on the day near $1,860. Although the 10-year US T-bond yield is down more than 1%, XAU/USD struggles to find demand on the last day of Q3.
Polkadot Price Forecast: DOT reversal seems inevitable after 92% correction from all-time high
Polkadot price, in nearly two years, has shed 92.91% from its all-time high of $55.09. The massive downswing in DOT has pushed it down to levels that were last seen in October 2020. Hence, the chances of this altcoin forming a bottom and rallying are high.
Earnings beat triggers Nike to spike 9%
Nike (NKE) stock has surged over 9% in Friday’s premarket, climbing above $98 per share, following late Thursday’s fiscal first-quarter earnings release. Nike beat pessimistic earnings expectations by more than 23% and hiked its dividend by 9%.